Related Experiment Video
Updated: Apr 17, 2026
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
18.8K
Improving access to novel agents for childhood leukemia
Weili Sun1,2, Paul S Gaynon1,2, Richard Sposto1,2
1Children's Center for Cancer and Blood Diseases, Division of Hematology, Oncology, and Blood and Marrow Transplantation, Children's Hospital Los Angeles, Los Angeles, California.
Cancer
|February 14, 2015
Summary
New treatments are needed for childhood leukemia, the most common pediatric cancer. This review explores strategies to improve access to novel therapies, aiming for higher cure rates and fewer side effects in young patients.
Area of Science:
- Pediatric Oncology
- Hematology
- Cancer Therapeutics
Background:
- Leukemia is the most common childhood cancer, posing a significant mortality risk.
- Survivors face long-term complications from current treatments.
- Novel therapeutic agents are crucial for improving cure rates and reducing treatment toxicity.
Purpose of the Study:
- To review strategies and initiatives for enhancing access to new therapeutic agents in pediatric leukemia treatment.
- To address the challenges in developing new therapies for childhood leukemia.
Main Methods:
- Literature review of current research and clinical trial initiatives.
- Analysis of challenges in pediatric leukemia drug development.
- Discussion of strategies to improve patient access to novel agents.
Main Results:
- Identified challenges include complex biology and small patient populations.
- Highlighted various initiatives aimed at accelerating drug development and access.
- Emphasized the need for collaborative efforts in pediatric cancer research.
Conclusions:
- Improving access to novel agents is critical for advancing pediatric leukemia treatment.
- Innovative strategies are necessary to overcome developmental and logistical hurdles.
- Further research and clinical trials are essential to bring new, less toxic therapies to children with leukemia.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
02:56Treatment Resistent Cancers
1.5K
1.5K
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
882
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
882
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
508
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
508
02:57Targeted Cancer Therapies
9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.2K